|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:IREB2-CTSH (FusionGDB2 ID:40051) |
Fusion Gene Summary for IREB2-CTSH |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: IREB2-CTSH | Fusion gene ID: 40051 | Hgene | Tgene | Gene symbol | IREB2 | CTSH | Gene ID | 3658 | 1512 |
| Gene name | iron responsive element binding protein 2 | cathepsin H | |
| Synonyms | ACO3|IRE-BP 2|IRE-BP2|IRP2|IRP2AD|NDCAMA | ACC-4|ACC-5|ACC4|ACC5|CPSB | |
| Cytomap | 15q25.1 | 15q25.1 | |
| Type of gene | protein-coding | protein-coding | |
| Description | iron-responsive element-binding protein 2iron regulatory protein 2 | pro-cathepsin HN-benzoylarginine-beta-naphthylamide hydrolasealeuraincathepsin B3cathepsin BA | |
| Modification date | 20200313 | 20200313 | |
| UniProtAcc | . | P09668 | |
| Ensembl transtripts involved in fusion gene | ENST00000258886, ENST00000560440, ENST00000559427, | ENST00000220166, ENST00000534533, | |
| Fusion gene scores | * DoF score | 12 X 7 X 7=588 | 5 X 4 X 3=60 |
| # samples | 12 | 5 | |
| ** MAII score | log2(12/588*10)=-2.29278174922785 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(5/60*10)=-0.263034405833794 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: IREB2 [Title/Abstract] AND CTSH [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | IREB2(78732223)-CTSH(79231513), # samples:2 | ||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | CTSH | GO:0002764 | immune response-regulating signaling pathway | 16822283 |
| Tgene | CTSH | GO:0006508 | proteolysis | 6203523|8811434 |
| Tgene | CTSH | GO:0010628 | positive regulation of gene expression | 21217776 |
| Tgene | CTSH | GO:0010813 | neuropeptide catabolic process | 15127951 |
| Tgene | CTSH | GO:0010815 | bradykinin catabolic process | 15127951 |
| Tgene | CTSH | GO:0010952 | positive regulation of peptidase activity | 20435891 |
| Tgene | CTSH | GO:0030335 | positive regulation of cell migration | 21217776 |
| Tgene | CTSH | GO:0031638 | zymogen activation | 20435891 |
| Tgene | CTSH | GO:0033619 | membrane protein proteolysis | 14766755 |
| Tgene | CTSH | GO:0043129 | surfactant homeostasis | 18216060 |
| Tgene | CTSH | GO:0070371 | ERK1 and ERK2 cascade | 21217776 |
| Fusion gene breakpoints across IREB2 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene breakpoints across CTSH (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | PRAD | TCGA-J4-AATZ | IREB2 | chr15 | 78732223 | + | CTSH | chr15 | 79231513 | - |
| ChimerDB4 | PRAD | TCGA-J4-AATZ-01A | IREB2 | chr15 | 78732223 | - | CTSH | chr15 | 79231513 | - |
Top |
Fusion Gene ORF analysis for IREB2-CTSH |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| In-frame | ENST00000258886 | ENST00000220166 | IREB2 | chr15 | 78732223 | + | CTSH | chr15 | 79231513 | - |
| 5CDS-intron | ENST00000258886 | ENST00000534533 | IREB2 | chr15 | 78732223 | + | CTSH | chr15 | 79231513 | - |
| In-frame | ENST00000560440 | ENST00000220166 | IREB2 | chr15 | 78732223 | + | CTSH | chr15 | 79231513 | - |
| 5CDS-intron | ENST00000560440 | ENST00000534533 | IREB2 | chr15 | 78732223 | + | CTSH | chr15 | 79231513 | - |
| intron-3CDS | ENST00000559427 | ENST00000220166 | IREB2 | chr15 | 78732223 | + | CTSH | chr15 | 79231513 | - |
| intron-intron | ENST00000559427 | ENST00000534533 | IREB2 | chr15 | 78732223 | + | CTSH | chr15 | 79231513 | - |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000258886 | IREB2 | chr15 | 78732223 | + | ENST00000220166 | CTSH | chr15 | 79231513 | - | 2244 | 255 | 149 | 1171 | 340 |
| ENST00000560440 | IREB2 | chr15 | 78732223 | + | ENST00000220166 | CTSH | chr15 | 79231513 | - | 2149 | 160 | 54 | 1076 | 340 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000258886 | ENST00000220166 | IREB2 | chr15 | 78732223 | + | CTSH | chr15 | 79231513 | - | 0.000612006 | 0.999388 |
| ENST00000560440 | ENST00000220166 | IREB2 | chr15 | 78732223 | + | CTSH | chr15 | 79231513 | - | 0.000596812 | 0.99940324 |
Top |
Fusion Genomic Features for IREB2-CTSH |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for IREB2-CTSH |
| Go to FGviewer for the breakpoints of chr15:78732223-chr15:79231513 - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| . | CTSH |
| FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. | FUNCTION: Important for the overall degradation of proteins in lysosomes. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for IREB2-CTSH |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >In-frame_ENST00000258886_ENST00000220166_TCGA-J4-AATZ_IREB2_chr15_78732223_+_CTSH_chr15_79231513_length(transcript)=2244nt_BP=255nt GCTCTGCTGCTCTCGCGATATTTGCGCGAGCCTGCTTCCTTCTTTCCTCCCTTGCCAGTCCGCCTGTCTTCCTCCCCGTCTTCCCTGCCC GGCCTCCCCCTTCTTCCCCCGCTGGCCCCCTCCCCGGAGGGATAATATGGTCTCCGGCGATGGACGCCCCAAAAGCAGGATACGCCTTTG AGTACCTTATTGAAACATTAAATGACAGTTCACATAAGAAGTTCTTCGATGTATCTAAACTTGGCACCAAGTATGAGAAGTTTCACTTCA AGTCATGGATGTCTAAGCACCGTAAGACCTACAGTACGGAGGAGTACCACCACAGGCTGCAGACGTTTGCCAGCAACTGGAGGAAGATAA ACGCCCACAACAATGGGAACCACACATTTAAAATGGCACTGAACCAATTTTCAGACATGAGCTTTGCTGAAATAAAACACAAGTATCTCT GGTCAGAGCCTCAGAATTGCTCAGCCACCAAAAGTAACTACCTTCGAGGTACTGGTCCCTACCCACCTTCCGTGGACTGGCGGAAAAAAG GAAATTTTGTCTCACCTGTGAAAAATCAGGGTGCCTGCGGCAGTTGCTGGACTTTCTCCACCACTGGGGCCCTGGAGTCTGCGATCGCCA TCGCAACCGGAAAGATGCTGTCCTTGGCGGAACAGCAGCTGGTGGACTGCGCCCAGGACTTCAATAATCACGGCTGCCAAGGGGGTCTCC CCAGCCAGGCTTTCGAGTATATCCTGTACAACAAGGGGATCATGGGTGAAGACACCTACCCCTACCAGGGCAAGGATGGTTATTGCAAGT TCCAACCTGGAAAGGCCATCGGCTTTGTCAAGGATGTAGCCAACATCACAATCTATGACGAGGAAGCGATGGTGGAGGCTGTGGCCCTCT ACAACCCTGTGAGCTTTGCCTTTGAGGTGACTCAGGACTTCATGATGTATAGAACCGGCATCTACTCCAGTACTTCCTGCCATAAAACTC CAGATAAAGTAAACCATGCAGTACTGGCTGTTGGGTATGGAGAAAAAAATGGGATCCCTTACTGGATCGTGAAAAACTCTTGGGGTCCCC AGTGGGGAATGAACGGGTACTTCCTCATCGAGCGCGGAAAGAACATGTGTGGCCTGGCTGCCTGCGCCTCCTACCCCATCCCTCTGGTGT GAGCCGTGGCAGCCGCAGCGCAGACTGGCGGAGAAGGAGAGGAACGGGCAGCCTGGGCCTGGGTGGAAATCCTGCCCTGGAGGAAGTTGT GGGGAGATCCACTGGGACCCCCAACATTCTGCCCTCACCTCTGTGCCCAGCCTGGAAACCTACAGACAAGGAGGAGTTCCACCATGAGCT CACCCGTGTCTATGACGCAAAGATCACCAGCCATGTGCCTTAGTGTCCTTCTTAACAGACTCAAACCACATGGACCACGAATATTCTTTC TGTCCAGAAGGGCTACTTTCCACATATAGAGCTCCAGGGACTGTCTTTTCTGTATTCGCTGTTCAATAAACATTGAGTGAGCACCTCCCC AGATGGAGCATGCTGGTCCTGGGCCATGACTCAAACCAGGTCTGTCCTCGCCACTCAGTCTCCCAGGAGGGAGGCATCAGGGGGTGTCCA GGCTCTGGCTGGGAGGATGGTGGGGGTGCTGGCGGTATTATCCACCAGATGGGGTATCCAGGATGAAGAGCAGGCTTAATTTGAGATCTT GACTATTTGTCCCAAACCTGAGTGGAGAGGTGGGGAGGAAGGAGAAAAACGGGCCAAGCTGCGGCAGAGGCAGGATTCAAACCCACAATG TCAGCCCAGAAGCCTGTACTTCTCTGTGTGGCCTCCCCAGTCTCAGCTGCCTACTCCTACTCAGACTCTGCCCCCCACCTCCACATGAGA CTGCCCACCCCTTCCTCACCAACCCCTTATTTATTTCAAACGTGCCCAGATGCTCCTGTCGTTTCCACACCATCCCTTCCCTTATCTTGC CTTTTGAGAAATCTTGATCTCTGTTTAGAGGGCGGCCATGAAGTTGCTGCTGCTTCCTGAAGCCTCCGGGCTCTGGGATGTCTGTAGAAC AAGCTGGAGTCCACCAGCTCTTTGTCCTATGGCTCACAGACTTTCTTAATGATAAAAGCTGTCATCTTATTTGGGCTTCCTGAAAAGCTA >In-frame_ENST00000258886_ENST00000220166_TCGA-J4-AATZ_IREB2_chr15_78732223_+_CTSH_chr15_79231513_length(amino acids)=340AA_start in transcript=149_stop in transcript=1171 MDAPKAGYAFEYLIETLNDSSHKKFFDVSKLGTKYEKFHFKSWMSKHRKTYSTEEYHHRLQTFASNWRKINAHNNGNHTFKMALNQFSDM SFAEIKHKYLWSEPQNCSATKSNYLRGTGPYPPSVDWRKKGNFVSPVKNQGACGSCWTFSTTGALESAIAIATGKMLSLAEQQLVDCAQD FNNHGCQGGLPSQAFEYILYNKGIMGEDTYPYQGKDGYCKFQPGKAIGFVKDVANITIYDEEAMVEAVALYNPVSFAFEVTQDFMMYRTG -------------------------------------------------------------- >In-frame_ENST00000560440_ENST00000220166_TCGA-J4-AATZ_IREB2_chr15_78732223_+_CTSH_chr15_79231513_length(transcript)=2149nt_BP=160nt CCCCCTTCTTCCCCCGCTGGCCCCCTCCCCGGAGGGATAATATGGTCTCCGGCGATGGACGCCCCAAAAGCAGGATACGCCTTTGAGTAC CTTATTGAAACATTAAATGACAGTTCACATAAGAAGTTCTTCGATGTATCTAAACTTGGCACCAAGTATGAGAAGTTTCACTTCAAGTCA TGGATGTCTAAGCACCGTAAGACCTACAGTACGGAGGAGTACCACCACAGGCTGCAGACGTTTGCCAGCAACTGGAGGAAGATAAACGCC CACAACAATGGGAACCACACATTTAAAATGGCACTGAACCAATTTTCAGACATGAGCTTTGCTGAAATAAAACACAAGTATCTCTGGTCA GAGCCTCAGAATTGCTCAGCCACCAAAAGTAACTACCTTCGAGGTACTGGTCCCTACCCACCTTCCGTGGACTGGCGGAAAAAAGGAAAT TTTGTCTCACCTGTGAAAAATCAGGGTGCCTGCGGCAGTTGCTGGACTTTCTCCACCACTGGGGCCCTGGAGTCTGCGATCGCCATCGCA ACCGGAAAGATGCTGTCCTTGGCGGAACAGCAGCTGGTGGACTGCGCCCAGGACTTCAATAATCACGGCTGCCAAGGGGGTCTCCCCAGC CAGGCTTTCGAGTATATCCTGTACAACAAGGGGATCATGGGTGAAGACACCTACCCCTACCAGGGCAAGGATGGTTATTGCAAGTTCCAA CCTGGAAAGGCCATCGGCTTTGTCAAGGATGTAGCCAACATCACAATCTATGACGAGGAAGCGATGGTGGAGGCTGTGGCCCTCTACAAC CCTGTGAGCTTTGCCTTTGAGGTGACTCAGGACTTCATGATGTATAGAACCGGCATCTACTCCAGTACTTCCTGCCATAAAACTCCAGAT AAAGTAAACCATGCAGTACTGGCTGTTGGGTATGGAGAAAAAAATGGGATCCCTTACTGGATCGTGAAAAACTCTTGGGGTCCCCAGTGG GGAATGAACGGGTACTTCCTCATCGAGCGCGGAAAGAACATGTGTGGCCTGGCTGCCTGCGCCTCCTACCCCATCCCTCTGGTGTGAGCC GTGGCAGCCGCAGCGCAGACTGGCGGAGAAGGAGAGGAACGGGCAGCCTGGGCCTGGGTGGAAATCCTGCCCTGGAGGAAGTTGTGGGGA GATCCACTGGGACCCCCAACATTCTGCCCTCACCTCTGTGCCCAGCCTGGAAACCTACAGACAAGGAGGAGTTCCACCATGAGCTCACCC GTGTCTATGACGCAAAGATCACCAGCCATGTGCCTTAGTGTCCTTCTTAACAGACTCAAACCACATGGACCACGAATATTCTTTCTGTCC AGAAGGGCTACTTTCCACATATAGAGCTCCAGGGACTGTCTTTTCTGTATTCGCTGTTCAATAAACATTGAGTGAGCACCTCCCCAGATG GAGCATGCTGGTCCTGGGCCATGACTCAAACCAGGTCTGTCCTCGCCACTCAGTCTCCCAGGAGGGAGGCATCAGGGGGTGTCCAGGCTC TGGCTGGGAGGATGGTGGGGGTGCTGGCGGTATTATCCACCAGATGGGGTATCCAGGATGAAGAGCAGGCTTAATTTGAGATCTTGACTA TTTGTCCCAAACCTGAGTGGAGAGGTGGGGAGGAAGGAGAAAAACGGGCCAAGCTGCGGCAGAGGCAGGATTCAAACCCACAATGTCAGC CCAGAAGCCTGTACTTCTCTGTGTGGCCTCCCCAGTCTCAGCTGCCTACTCCTACTCAGACTCTGCCCCCCACCTCCACATGAGACTGCC CACCCCTTCCTCACCAACCCCTTATTTATTTCAAACGTGCCCAGATGCTCCTGTCGTTTCCACACCATCCCTTCCCTTATCTTGCCTTTT GAGAAATCTTGATCTCTGTTTAGAGGGCGGCCATGAAGTTGCTGCTGCTTCCTGAAGCCTCCGGGCTCTGGGATGTCTGTAGAACAAGCT GGAGTCCACCAGCTCTTTGTCCTATGGCTCACAGACTTTCTTAATGATAAAAGCTGTCATCTTATTTGGGCTTCCTGAAAAGCTAAAGGC >In-frame_ENST00000560440_ENST00000220166_TCGA-J4-AATZ_IREB2_chr15_78732223_+_CTSH_chr15_79231513_length(amino acids)=340AA_start in transcript=54_stop in transcript=1076 MDAPKAGYAFEYLIETLNDSSHKKFFDVSKLGTKYEKFHFKSWMSKHRKTYSTEEYHHRLQTFASNWRKINAHNNGNHTFKMALNQFSDM SFAEIKHKYLWSEPQNCSATKSNYLRGTGPYPPSVDWRKKGNFVSPVKNQGACGSCWTFSTTGALESAIAIATGKMLSLAEQQLVDCAQD FNNHGCQGGLPSQAFEYILYNKGIMGEDTYPYQGKDGYCKFQPGKAIGFVKDVANITIYDEEAMVEAVALYNPVSFAFEVTQDFMMYRTG -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for IREB2-CTSH |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for IREB2-CTSH |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for IREB2-CTSH |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | IREB2 | C0027626 | Neoplasm Invasiveness | 1 | CTD_human |
| Tgene | CTSH | C0011854 | Diabetes Mellitus, Insulin-Dependent | 1 | CTD_human |
| Tgene | CTSH | C0023467 | Leukemia, Myelocytic, Acute | 1 | CTD_human |
| Tgene | CTSH | C0026998 | Acute Myeloid Leukemia, M1 | 1 | CTD_human |
| Tgene | CTSH | C0027404 | Narcolepsy | 1 | ORPHANET |
| Tgene | CTSH | C0205734 | Diabetes, Autoimmune | 1 | CTD_human |
| Tgene | CTSH | C0342302 | Brittle diabetes | 1 | CTD_human |
| Tgene | CTSH | C0751362 | Narcolepsy-Cataplexy Syndrome | 1 | ORPHANET |
| Tgene | CTSH | C1879321 | Acute Myeloid Leukemia (AML-M2) | 1 | CTD_human |
| Tgene | CTSH | C3837958 | Diabetes Mellitus, Ketosis-Prone | 1 | CTD_human |
| Tgene | CTSH | C4554117 | Diabetes Mellitus, Sudden-Onset | 1 | CTD_human |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies